Longitudinal lung function in idiopathic NSIP: what are we missing?

Chen H., Gomez A., Shum A., Collard H. R.

Source: Eur Respir J 2009; 34: 1004
Journal Issue: October
Disease area: Interstitial lung diseases

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Chen H., Gomez A., Shum A., Collard H. R.. Longitudinal lung function in idiopathic NSIP: what are we missing?. Eur Respir J 2009; 34: 1004

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Outcome differences between idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILD) - data from the EXCITING registry
Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries
Year: 2018



Do typical and atypical HRCT patterns make difference in prognosis of patients with IPF?
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016

Quality of life of patients with idiopathic pulmonary fibrosis (IPF) - What can the Australian IPF registry tell us?
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015



Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016


6MWT performance by means of Spiropalm in patients affected by fibrotic idiopathic interstitial pneumonias: Preliminary observations
Source: International Congress 2014 – ILDs 6
Year: 2014


Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases
Year: 2012

The decline in lung function is related to both emphysema and fibrosis extent in patients with idiopathic pulmonary fibrosis (IPF)/ combined pulmonary fibrosis and emphysema (CPFE)
Source: International Congress 2014 – ILDs 1
Year: 2014


The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016

Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom?
Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment
Year: 2006


Longitudinal observation of idiopathic pulmonary fibrosis (IPF) patients cohort from one center in Poland.
Source: International Congress 2019 – Interstitial lung disease registries
Year: 2019

Can clinical data predict rapid decline of lung function in idiopathic pulmonary fibrosis (IPF) patients?
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017

Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016


Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – ILDs 3
Year: 2014


Corticosteroids determine clinical course of IIPs with possible UIP HRCT pattern?
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016

Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP)
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013

Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015


Analysis of baseline characteristics by emphysema extent in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017


Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016


Assessment of nutritional status in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases
Year: 2016